Glaukos Co. (NYSE:GKOS - Get Free Report) CFO Alex R. Thurman sold 474 shares of the company's stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $90.37, for a total transaction of $42,835.38. Following the sale, the chief financial officer now owns 54,916 shares of the company's stock, valued at $4,962,758.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Glaukos Stock Up 5.4 %
Shares of NYSE:GKOS opened at $94.31 on Thursday. Glaukos Co. has a 12 month low of $45.38 and a 12 month high of $97.75. The company has a 50-day moving average price of $90.68 and a 200-day moving average price of $78.91. The company has a quick ratio of 4.78, a current ratio of 5.34 and a debt-to-equity ratio of 0.77.
Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.07). Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The company had revenue of $82.40 million during the quarter, compared to the consensus estimate of $81.00 million. During the same period in the previous year, the company earned ($0.53) earnings per share. Glaukos's quarterly revenue was up 15.7% on a year-over-year basis. Equities research analysts expect that Glaukos Co. will post -2.18 earnings per share for the current year.
Institutional Inflows and Outflows
He Is Giving Away Bitcoin
From Crypto Swap Profits | Ad
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously.
Right now is a very important time to pay attention to what we are doing and what is happening.
If you wait... it will be too late.
This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
>> Register right here
Several institutional investors have recently added to or reduced their stakes in GKOS. National Bank of Canada FI bought a new position in Glaukos in the fourth quarter worth approximately $46,000. GAMMA Investing LLC bought a new position in Glaukos in the fourth quarter worth approximately $55,000. Tower Research Capital LLC TRC raised its position in Glaukos by 257.8% in the first quarter. Tower Research Capital LLC TRC now owns 1,238 shares of the medical instruments supplier's stock worth $62,000 after acquiring an additional 892 shares during the period. Silverarc Capital Management LLC bought a new position in Glaukos in the second quarter worth approximately $71,000. Finally, Quadrant Capital Group LLC raised its position in Glaukos by 54.8% in the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier's stock worth $74,000 after acquiring an additional 329 shares during the period. 99.04% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
GKOS has been the subject of several analyst reports. Piper Sandler upped their price target on shares of Glaukos from $90.00 to $105.00 and gave the company an "overweight" rating in a research report on Friday, December 22nd. StockNews.com lowered shares of Glaukos from a "hold" rating to a "sell" rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. upgraded shares of Glaukos from a "neutral" rating to an "overweight" rating and upped their price target for the company from $66.00 to $91.00 in a research report on Thursday, December 21st. Citigroup upped their price target on shares of Glaukos from $107.00 to $120.00 and gave the company a "buy" rating in a research report on Monday, March 25th. Finally, Wells Fargo & Company upped their price objective on shares of Glaukos from $83.00 to $103.00 and gave the company an "overweight" rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $98.30.
Check Out Our Latest Research Report on GKOS
About Glaukos
(
Get Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
